Angelo Tzarevski

Angelo regularly advises domestic and international clients on all aspects of competition law, including merger control, cartel investigations, prohibited practices, horizontal and vertical arrangements, abuse of dominance, and corporate leniency. He has acted for clients in diverse industries including pharmaceuticals, chemicals, banking, private equity, automotive, petroleum, healthcare, mining and construction, consumer goods, aviation, and telecommunications.

• Hitachi, Inc. in successfully obtaining merger clearance in South Africa and Namibia in respect of its global acquisition of the power grid business of Swiss-based ABB Ltd. valued at USD 11 billion.

• GlaxoSmithKline in obtaining merger clearance in South Africa for its USD 12.7 billion acquisition of the global consumer healthcare business of Pfizer, Inc.

• German pharmaceutical company on the South African merger control aspects of the disposal of one of its specialty businesses in a global transaction valued at approximately USD 7 billion.

• Archer-Daniels-Midland on the Malagasy merger control aspects of a series of transactions involving a full-function joint venture.

• Russian vertically integrated steel making and mining company in successfully blocking the hostile takeover of its South African businesses.

• French and Danish private equity funds in relation to COMESA merger control issues in a complex transaction involving the acquisition of businesses in Mauritius, Kenya and Malawi.

• Archer-Daniels-Midland in successfully obtaining clearance in South Africa for its EUR 1.5 billion acquisition of Neovia.

• Fluidra S.A., a listed Spanish manufacturer of swimming pool equipment, in successfully obtaining clearance in South Africa for its merger involving Rhone Capital LLC valued at EUR 1 billion.

• Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), a multinational specialty pharmaceutical company, in successfully obtaining merger approval in South Africa and Namibia for the sale of its global subsidiary, iNova Pharmaceuticals, to a private equity consortium for USD 930 million.

• US-based private equity firm in relation to merger control issues in a transaction involving Kenya, Tanzania, Malawi, Botswana, Mauritius, Namibia, Zambia, Zimbabwe, and COMESA.

• US-based private equity firm in successfully obtaining merger clearances in COMESA, Malawi and South Africa for the acquisition of control over a cross-border payment system and money transfer provider.

Antitrust/Regulatory:

• Unilever in relation to ongoing complaint proceedings by the South African antitrust authorities involving allegations of cartel conduct.

• International conglomerate in relation to antitrust claims instituted by the purchasers of its former media business who are facing ongoing investigations and prosecutions by the South African competition authorities.

• Global media distribution, sports, events and talent management company in relation to leniency proceedings in South Africa.

• Japanese automotive parts supplier in settlement negotiations with the South African competition authority relating to allegations of participation in a global cartel.

• Defending a number of clients in the chemical, pharmaceutical and luxury goods industries in successfully defending themselves against complaints in South Africa involving allegations of abuse of dominance.

• International Bar Association - Member 
• Law Society of the Northern Provinces - Member